Logo image of CMD

Cantel Medical (CMD) Stock Fundamental Analysis

NYSEARCA:CMD - NYSE Arca -

80.37  -0.96 (-1.18%)

After market: 80.37 0 (0%)

Fundamental Rating

3

Taking everything into account, CMD scores 3 out of 10 in our fundamental rating. CMD was compared to 190 industry peers in the Health Care Equipment & Supplies industry. CMD has a bad profitability rating. Also its financial health evaluation is rather negative. CMD is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

CMD had positive earnings in the past year.

1.2 Ratios

Industry RankSector Rank
ROA 2.56%
ROE 6.37%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

Industry RankSector Rank
OM 11.54%
PM (TTM) 4.57%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

3

2. Health

2.1 Basic Checks

There is no outstanding debt for CMD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

An Altman-Z score of 2.98 indicates that CMD is not a great score, but indicates only limited risk for bankruptcy at the moment.
CMD has a Debt/Equity ratio of 0.90. This is a neutral value indicating CMD is somewhat dependend on debt financing.
Industry RankSector Rank
Debt/Equity 0.9
Debt/FCF N/A
Altman-Z 2.98
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

CMD has a Current Ratio of 2.58. This indicates that CMD is financially healthy and has no problem in meeting its short term obligations.
CMD has a Quick Ratio of 1.84. This is a normal value and indicates that CMD is financially healthy and should not expect problems in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 2.58
Quick Ratio 1.84

More info and screens

6

3. Growth

3.1 Past

CMD shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -29.96%.
The Earnings Per Share has been growing by 25.92% on average over the past years. This is a very strong growth
Looking at the last year, CMD shows a quite strong growth in Revenue. The Revenue has grown by 11.37% in the last year.
The Revenue has been growing by 12.45% on average over the past years. This is quite good.
EPS 1Y (TTM)-29.96%
EPS 3Y-4.57%
EPS 5Y25.92%
EPS Q2Q%27.03%
Revenue 1Y (TTM)11.37%
Revenue growth 3Y9.68%
Revenue growth 5Y12.45%
Sales Q2Q%32.51%

3.2 Future

The Earnings Per Share is expected to grow by 21.07% on average over the next years. This is a very strong growth
CMD is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 8.80% yearly.
EPS Next Y82.92%
EPS Next 2Y37.5%
EPS Next 3Y29.83%
EPS Next 5Y21.07%
Revenue Next Year17.48%
Revenue Next 2Y11.96%
Revenue Next 3Y10.48%
Revenue Next 5Y8.8%

3.3 Evolution

The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
CMD Yearly Revenue VS EstimatesCMD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B
CMD Yearly EPS VS EstimatesCMD Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1 2 3 4

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 48.42, the valuation of CMD can be described as expensive.
CMD is valuated expensively when we compare the Price/Earnings ratio to 29.63, which is the current average of the S&P500 Index.
Based on the Price/Forward Earnings ratio of 25.61, the valuation of CMD can be described as expensive.
When comparing the Price/Forward Earnings ratio of CMD to the average of the S&P500 Index (22.68), we can say CMD is valued inline with the index average.
Industry RankSector Rank
PE 48.42
Fwd PE 25.61
CMD Price Earnings VS Forward Price EarningsCMD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA 19.45
CMD Per share dataCMD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15 20 25

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
CMD's earnings are expected to grow with 29.83% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.58
PEG (5Y)1.87
EPS Next 2Y37.5%
EPS Next 3Y29.83%

More info and screens

2

5. Dividend

5.1 Amount

CMD has a yearly dividend return of 0.13%, which is pretty low.
With a Dividend Yield of 0.13, CMD pays less dividend than the S&P500 average, which is at 2.27.
Industry RankSector Rank
Dividend Yield 0.13%

5.2 History

On average, the dividend of CMD grows each year by 25.79%, which is quite nice.
CMD has paid a dividend for less than 5 years, so there is no long track record yet.
Dividend Growth(5Y)25.79%
Div Incr YearsN/A
Div Non Decr YearsN/A
CMD Yearly Dividends per shareCMD Yearly Dividends per shareYearly Dividends per share 2018 2019 2020 0.05 0.1 0.15

5.3 Sustainability

The dividend of CMD is growing, but the earnings are growing slower. This means the dividend growth is not sustainable.
DP0%
EPS Next 2Y37.5%
EPS Next 3Y29.83%

More info and screens

Cantel Medical

NYSEARCA:CMD (6/1/2021, 8:24:59 PM)

After market: 80.37 0 (0%)

80.37

-0.96 (-1.18%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners0.32%
Ins Owner Change0%
Market Cap3.58B
Analysts65
Price Target63.24 (-21.31%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0.13%
Yearly Dividend0.11
Dividend Growth(5Y)25.79%
DP0%
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 48.42
Fwd PE 25.61
P/S 3.14
P/FCF N/A
P/OCF N/A
P/B 4.38
P/tB N/A
EV/EBITDA 19.45
EPS(TTM)1.66
EY2.07%
EPS(NY)3.14
Fwd EY3.91%
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS25.57
BVpS18.36
TBVpSN/A
PEG (NY)0.58
PEG (5Y)1.87
Profitability
Industry RankSector Rank
ROA 2.56%
ROE 6.37%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM 11.54%
PM (TTM) 4.57%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y0%
ROICexcg growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score9
Asset Turnover0.56
Health
Industry RankSector Rank
Debt/Equity 0.9
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.58
Quick Ratio 1.84
Altman-Z 2.98
F-Score9
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-29.96%
EPS 3Y-4.57%
EPS 5Y25.92%
EPS Q2Q%27.03%
EPS Next Y82.92%
EPS Next 2Y37.5%
EPS Next 3Y29.83%
EPS Next 5Y21.07%
Revenue 1Y (TTM)11.37%
Revenue growth 3Y9.68%
Revenue growth 5Y12.45%
Sales Q2Q%32.51%
Revenue Next Year17.48%
Revenue Next 2Y11.96%
Revenue Next 3Y10.48%
Revenue Next 5Y8.8%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A